ClinicalTrials.gg
CompletedNCT05138822Updated Mar 13, 2026Results posted

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

A Phase 1 interventional study of GSK3882347 and Nitrofurantoin in Uncomplicated Urinary Tract Infections and Urinary Tract Infections, sponsored by GlaxoSmithKline. Completed at 15 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
5th of 13
140 · median 61
Started
2022
the only one that year
Phase 1
5 of 14
2 open now
Registered
7th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 1, and was the 7th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response following oral dosing for 5 days of GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator nitrofurantoin will be included in the study to ensure unbiased reporting of safety events. The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment period and PK analysis conducted less frequently, at key trough timepoints.

03

Conditions studied

  • Uncomplicated Urinary Tract Infections
  • Urinary Tract Infections

Keywords

  • Microbiological response
  • Urinary tract infections (UTI)
  • GSK3882347
  • Nitrofurantoin
  • Pharmacokinetics
  • Escherichia coli (E. coli)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be greater than or equal to (>=)18 years of age and less than or equal to (\<=)70 years
  • The participant has 2 or more of the following clinical signs and symptoms of uncomplicated urinary tract infections (uUTI) with onset less than (\<) 96 hours of the screening assessment: dysuria, frequency, urgency, or lower abdominal pain
  • Participant has nitrite OR pyuria (≥ 10 white blood cells/ cubic millimeter [WBC/mm\^3], OR > 5 WBC/high power field [HPF]) OR the presence of 2+ leukocyte esterase from a pre-treatment clean-catch midstream urine sample
  • Participants with (BMI) >= 19.0 kilograms per square meter (kg/m\^2)
  • A female participant is eligible to participate who is not pregnant (as confirmed by a highly sensitive pregnancy test before the first dose of study intervention) or breastfeeding and one of the following conditions apply: 1) Woman participant of non- (WONCBP) Or 2) Woman participant of childbearing potential (WOCBP) using a method that is highly effective, with a failure rate of \< 1 percentage (%), during the study intervention period and up to 5 days post intervention
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol.

Exclusion criteria

Exclusion Criteria:

  • The participant has a >= 40.0 kg/ m\^2 or a BMI >=35.0 kg/ m\^2 with obesity related health conditions such as high blood pressure or uncontrolled diabetes (non-fasting glucose value >300 milligram/deciliter [mg/dL])
  • The participant is or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications
  • The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis
  • The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction of the urinary tract, primary renal disease, or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract
  • The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract
  • The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptoms onset >=96 hours before the screening assessment, or a temperature >=101-degree Fahrenheit (°F) (>=38 degree Celsius [°C]), flank pain, chills, or any other manifestations suggestive of upper UTI
  • The participant has anuria, oliguria, or significant impairment of renal function
  • The participant presents at enrollment with a suspected sexually transmitted infection
  • A positive confirmation of Coronavirus Disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19
  • The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week or 10 weeks for dalbavancin or oritavancin before study entry.
  • Regular alcohol consumption within 6 months prior to the study with an average weekly intake of >14 units for females and one unit is equivalent to approximately 8 g of alcohol: a half-pint (250 mL) of beer, one glass (125 mL) of wine or one (35 mL) measure of spirits
  • Unable to take nitrofurantoin. E.g. to the active substance
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    GSK3882347+ Placebo

    Participants received GSK3882347 oral capsules plus placebo oral capsules from Day 1 to Day 5.

    Drug: GSK3882347 · Drug: Placebo

  • Active comparator
    Nitrofurantoin + Placebo

    Participants received 100 milligrams (mg) of nitrofurantoin oral capsules plus placebo oral capsules from Day 1 to Day 5.

    Drug: Nitrofurantoin · Drug: Placebo

Interventions

  • GSK3882347 was administered.

  • Nitrofurantoin was administered.

  • DrugPlacebo

    Placebo matching GSK3882347 or Nitrofurantoin was administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit

    Microbiological response (success/failure) is used to measure microbiological efficacy. Microbiological success was defined as a reduction in E. coli count to less than (\<) 10\^3 colony-forming units (CFU) per milliliter (CFU/mL) for any E. coli at the ToC visit. Microbiological failure included all other microbiological outcomes (for example but not limited to \>=10\^3 CFU/mL for any E. coli identified at ToC visit, use of rescue medication prior to ToC, lost to follow-up before ToC, missing/unevaluable samples at ToC, etc).

    Time frame: Day 10 to Day 13 (ToC Visit)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From the first dose of study intervention up to Follow-up Visit (up to Day 31)

  2. Number of Participants With Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; or any other situation according to the medical or scientific judgment of the investigator.

    Time frame: From the signing of informed consent up to Follow-up Visit (up to Day 31)

  3. Number of Participants With Clinically Significant Changes in Vital Signs Findings

    Vital signs included tympanic-measured temperature, pulse and respiratory rate, systolic and diastolic blood pressure. Blood pressure and pulse measurements were assessed in a semi-supine or seated position with a completely automated device and were measured after at least 10 minutes of rest for the participant in a quiet setting without distractions. Clinical significance of any change in vital signs was determined by the investigator.

    Time frame: Up to Day 31

  4. Number of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings

    Twelve-lead ECGs were obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of any change in ECG findings was determined by the investigator.

    Time frame: Up to Day 31

  5. Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples were collected for hematology parameters including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, reticulocytes, white blood cell (WBC) count (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Clinical significance of any change in hematology parameters was determined by the investigator.

    Time frame: Up to Day 31

  6. Number of Participants With Clinically Significant Changes in Chemistry Parameters

    Blood samples were collected for chemistry parameters including blood urea nitrogen (BUN), creatinine (including estimated glomerular filtration rate \[eGFR\]), glucose (non-fasting), potassium, sodium, calcium, total and direct bilirubin, total protein, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase. Clinical significance of any change in clinical chemistry parameters was determined by the investigator.

    Time frame: Up to Day 31

  7. Number of Participants With Clinically Significant Changes in Urinalysis Parameters

    Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, microscopic examination (if blood or protein was abnormal), and protein/creatinine ratio. Clinical significance of any change in urinalysis parameters was determined by the investigator.

    Time frame: Up to Day 31

  8. Cohort 1: Plasma Concentration at the End of the Dosing Interval Tau (Ctau) of GSK3882347 Post-dose on Day 1 and Day 5

    Time frame: 24 hours post-dose on Day 1 and Day 5

  9. Cohort 1: Urine Concentration of GSK3882347 at 22-24-hour (h) Interval Collection Post-dose on Day 1 and Day 5

    Time frame: 22-24 hour interval post-dose on Day 1 and Day 5

  10. Cohort 2: Plasma Ctau of GSK3882347 Post-dose on Day 1 and Day 5

    Time frame: 24 hours post-dose on Day 1 and Day 5

  11. Cohort 2: Urine Concentration of GSK3882347 at 22-24h Interval Collection Post-dose on Day 1 and Day 5

    Time frame: 22-24 hour interval post-dose on Day 1 and Day 5

Other outcomes

  1. Number of Participants With Clinical Symptom Score Outcome

    Clinical symptom score (CSS) measures 4 uncomplicated urinary tract infection (uUTI) symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome for a visit is categorized based on change of total score from baseline (BL): Clinical Resolution (CR) - Total score decreases from BL to 0; Clinical Improvement (CI) - Total score decreases from BL but is greater than (\>) 0; Clinical Worsening (CW) - Total score increases or has no change from BL; or Indeterminate (Ind) - Participant (par.) failed to attend the visit, achieved CR/CI but received systemic antibacterials between BL and the visit day being assessed, or BL score is missing. For a clinical outcome of CR/CI, the par. must not have received another systemic antibacterials between BL and the visit being assessed.

    Time frame: Day 2 to Day 6

  2. Number of Participants With Clinical Symptom Score Response at the ToC Visit

    CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome at ToC is categorized based on change of total score from BL: CR - Total score decreases from BL to 0; CI - Total score decreases from BL but is \>0; CW - Total score increases or has no change from BL; Ind - Par. refused a clinical examination, failed to attend the ToC visit, achieved CR or CI but received another systemic antibacterial before ToC, or BL score is missing. For a clinical outcome of CR or CI, the par. must not have received another systemic antibacterial between BL and ToC visit. Clinical response at ToC is defined as "Clinical Success" for an outcome of CR, and "Clinical Failure" for any other outcome (CI, CW, or Ind).

    Time frame: Day 10 to Day 13 (ToC Visit)

  3. Number of Participants With Clinical Symptom Score Response at the Follow-up (FU) Visit

    CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Individual symptoms (each scored 0 to 3) are added for a total score (0-12), with higher scores indicating greater severity. Clinical outcome at FU is categorized based on change of total score from ToC: Sustained CR (SCR) - ToC and FU=0; Delayed CR (DCR) - FU=0, after \>0 at ToC; CI - Total score at FU and ToC\>0, with score at FU\<ToC; CW - Total score at FU and ToC\>0, with score at FU\>ToC; Clinical Recurrence (CRr) - Total score \>0 at FU after ToC=0; Ind - Par. refused a clinical exam, failed to attend FU, achieved SCR/DCR/CI but received another systemic antibacterials before ToC, or BL score is missing. For a clinical outcome of SCR/DCR/CI, the par. must not have received any systemic antibacterials between BL and FU. Clinical response at FU is defined as "Clinical Success" for an outcome of SCR, and "Clinical Failure" for any other outcome (DCR, CI, CW, CRr, or Ind).

    Time frame: Day 25 to Day 31 (Follow-up Visit)

  4. Number of Participants With Clinical Resolution Response Outcome

    The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution outcome was reported as Clinically Resolved if, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. Refusal to consent to a clinical examination at a required in-person visit or failure to attend the visit had an outcome of Indeterminate.

    Time frame: Day 2 to Day 6

  5. Number of Participants With Clinical Resolution Response at the ToC Visit

    The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at ToC visit was defined as "Clinical Resolution Success (CRS)" when, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. "Clinical Resolution Failure (CRF)" was defined when investigator's assessment was Clinically Unresolved/Clinical Worsening or Indeterminate at ToC. Indeterminate was defined as refusal to consent to a clinical examination or failure to attend the ToC visit.

    Time frame: Day 10 to Day 13 (ToC Visit)

  6. Number of Participants With Clinical Resolution Response at the Follow-up (FU) Visit

    The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at FU was defined as "CRS" when investigator's assessment was Clinically Resolved at both ToC and FU (SCR), i.e., resolution of signs and symptoms of the uUTI present at BL (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterials. "CRF" was defined when investigator's assessment was: Clinically Unresolved at ToC but Clinically Resolved at FU (DCR); Clinically Resolved at ToC but Clinically Unresolved at FU (CRr); Clinically Unresolved at both ToC and FU (CU/CW); or when participants refused to consent to a clinical exam, failed to attend the FU, or achieved SCR/DCR but received other systemic antibacterials before FU (Ind).

    Time frame: Day 25 to Day 31 (Follow-up Visit)

07

Results

Posted Mar 13, 2026
Limitations and caveats
Due to potential data quality issues, 14 participants were excluded from the analyses presented. Only 1 out of these 14 participants was in the defined Micro-MPP analysis set. Hence, any analysis presented here using the Micro-MPP analysis set excludes this 1 participant.

Participant flow

Participant flow — Overall Study
MilestoneNitrofurantoin + PlaceboGSK3882347+ Placebo
Started35105
Safety analysis set34102
Pharmacokinetic (pk) analysis set3399
Microbiological modified per protocol (micro-mpp) analysis set1129
Completed3194
Not completed411
Withdrew: Lost to follow-up01
Withdrew: Protocol violation18
Withdrew: Physician decision10
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryNumber of Participants With Microbiological Response at the Test of Cure (ToC) Visit

Microbiological response (success/failure) is used to measure microbiological efficacy. Microbiological success was defined as a reduction in E. coli count to less than (\<) 10\^3 colony-forming units (CFU) per milliliter (CFU/mL) for any E. coli at the ToC visit. Microbiological failure included all other microbiological outcomes (for example but not limited to \>=10\^3 CFU/mL for any E. coli identified at ToC visit, use of rescue medication prior to ToC, lost to follow-up before ToC, missing/unevaluable samples at ToC, etc).

Time frame:
Day 10 to Day 13 (ToC Visit)
Reported as:
Count of participants · Participants
Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Microbiological Success1010
Microbiological Failure118
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
From the first dose of study intervention up to Follow-up Visit (up to Day 31)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Adverse Events (AEs)1022
SecondaryNumber of Participants With Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; or any other situation according to the medical or scientific judgment of the investigator.

Time frame:
From the signing of informed consent up to Follow-up Visit (up to Day 31)
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs (SAEs)
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Serious AEs (SAEs)00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs Findings

Vital signs included tympanic-measured temperature, pulse and respiratory rate, systolic and diastolic blood pressure. Blood pressure and pulse measurements were assessed in a semi-supine or seated position with a completely automated device and were measured after at least 10 minutes of rest for the participant in a quiet setting without distractions. Clinical significance of any change in vital signs was determined by the investigator.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs Findings
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Clinically Significant Changes in Vital Signs Findings00
SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings

Twelve-lead ECGs were obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. Clinical significance of any change in ECG findings was determined by the investigator.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECG) Findings00
SecondaryNumber of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples were collected for hematology parameters including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, reticulocytes, white blood cell (WBC) count (neutrophils, lymphocytes, monocytes, eosinophils, basophils). Clinical significance of any change in hematology parameters was determined by the investigator.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Hematology Parameters
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Clinically Significant Changes in Hematology Parameters22
SecondaryNumber of Participants With Clinically Significant Changes in Chemistry Parameters

Blood samples were collected for chemistry parameters including blood urea nitrogen (BUN), creatinine (including estimated glomerular filtration rate \[eGFR\]), glucose (non-fasting), potassium, sodium, calcium, total and direct bilirubin, total protein, aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase. Clinical significance of any change in clinical chemistry parameters was determined by the investigator.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Chemistry Parameters
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Clinically Significant Changes in Chemistry Parameters13
SecondaryNumber of Participants With Clinically Significant Changes in Urinalysis Parameters

Urine samples were collected for the analysis of urine parameters including specific gravity, potential of hydrogen (pH), glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, microscopic examination (if blood or protein was abnormal), and protein/creatinine ratio. Clinical significance of any change in urinalysis parameters was determined by the investigator.

Time frame:
Up to Day 31
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Urinalysis Parameters
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Number of Participants With Clinically Significant Changes in Urinalysis Parameters00
SecondaryCohort 1: Plasma Concentration at the End of the Dosing Interval Tau (Ctau) of GSK3882347 Post-dose on Day 1 and Day 5
Time frame:
24 hours post-dose on Day 1 and Day 5

Results for this outcome have not been posted.

SecondaryCohort 1: Urine Concentration of GSK3882347 at 22-24-hour (h) Interval Collection Post-dose on Day 1 and Day 5
Time frame:
22-24 hour interval post-dose on Day 1 and Day 5

Results for this outcome have not been posted.

SecondaryCohort 2: Plasma Ctau of GSK3882347 Post-dose on Day 1 and Day 5
Time frame:
24 hours post-dose on Day 1 and Day 5

Results for this outcome have not been posted.

SecondaryCohort 2: Urine Concentration of GSK3882347 at 22-24h Interval Collection Post-dose on Day 1 and Day 5
Time frame:
22-24 hour interval post-dose on Day 1 and Day 5

Results for this outcome have not been posted.

Other pre-specifiedNumber of Participants With Clinical Symptom Score Outcome

Clinical symptom score (CSS) measures 4 uncomplicated urinary tract infection (uUTI) symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome for a visit is categorized based on change of total score from baseline (BL): Clinical Resolution (CR) - Total score decreases from BL to 0; Clinical Improvement (CI) - Total score decreases from BL but is greater than (\>) 0; Clinical Worsening (CW) - Total score increases or has no change from BL; or Indeterminate (Ind) - Participant (par.) failed to attend the visit, achieved CR/CI but received systemic antibacterials between BL and the visit day being assessed, or BL score is missing. For a clinical outcome of CR/CI, the par. must not have received another systemic antibacterials between BL and the visit being assessed.

Time frame:
Day 2 to Day 6
Reported as:
Count of participants · Participants
Number of Participants With Clinical Symptom Score Outcome
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Day 2 - Clinical Resolution (CR)01
Day 2 - Clinical Improvement (CI)819
Day 2 - Clinical Worsening (CW)38
Day 3 - Clinical Improvement (CI)21
Day 4 - Clinical Resolution (CR)25
Day 4 - Clinical Improvement (CI)922
Day 4 - Clinical Worsening (CW)01
Day 5 - Clinical Resolution (CR)21
Day 6 - Clinical Resolution (CR)914
Day 6 - Clinical Improvement (CI)213
Day 6 - Clinical Worsening (CW)01
Other pre-specifiedNumber of Participants With Clinical Symptom Score Response at the ToC Visit

CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Each symptom is scored from 0 (no symptoms) to 3 (severe). Individual symptom scores are added for a cumulative total score (range 0-12), with higher scores indicating greater severity. Clinical outcome at ToC is categorized based on change of total score from BL: CR - Total score decreases from BL to 0; CI - Total score decreases from BL but is \>0; CW - Total score increases or has no change from BL; Ind - Par. refused a clinical examination, failed to attend the ToC visit, achieved CR or CI but received another systemic antibacterial before ToC, or BL score is missing. For a clinical outcome of CR or CI, the par. must not have received another systemic antibacterial between BL and ToC visit. Clinical response at ToC is defined as "Clinical Success" for an outcome of CR, and "Clinical Failure" for any other outcome (CI, CW, or Ind).

Time frame:
Day 10 to Day 13 (ToC Visit)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Symptom Score Response at the ToC Visit
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Clinical Success1121
Clinical Improvement (CI)05
Clinical Worsening (CW)01
Indeterminate (Ind)01
Other pre-specifiedNumber of Participants With Clinical Symptom Score Response at the Follow-up (FU) Visit

CSS measures 4 uUTI symptoms: dysuria, frequency, urgency, and lower abdominal/suprapubic pain. Individual symptoms (each scored 0 to 3) are added for a total score (0-12), with higher scores indicating greater severity. Clinical outcome at FU is categorized based on change of total score from ToC: Sustained CR (SCR) - ToC and FU=0; Delayed CR (DCR) - FU=0, after \>0 at ToC; CI - Total score at FU and ToC\>0, with score at FU\<ToC; CW - Total score at FU and ToC\>0, with score at FU\>ToC; Clinical Recurrence (CRr) - Total score \>0 at FU after ToC=0; Ind - Par. refused a clinical exam, failed to attend FU, achieved SCR/DCR/CI but received another systemic antibacterials before ToC, or BL score is missing. For a clinical outcome of SCR/DCR/CI, the par. must not have received any systemic antibacterials between BL and FU. Clinical response at FU is defined as "Clinical Success" for an outcome of SCR, and "Clinical Failure" for any other outcome (DCR, CI, CW, CRr, or Ind).

Time frame:
Day 25 to Day 31 (Follow-up Visit)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Symptom Score Response at the Follow-up (FU) Visit
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Clinical Success1019
Delayed Clinical Resolution (DCR)03
Clinical Improvement (CI)02
Clinical Recurrence (CRr)11
Clinical Worsening (CW)01
Indeterminate (Ind)02
Other pre-specifiedNumber of Participants With Clinical Resolution Response Outcome

The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution outcome was reported as Clinically Resolved if, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. Refusal to consent to a clinical examination at a required in-person visit or failure to attend the visit had an outcome of Indeterminate.

Time frame:
Day 2 to Day 6
Reported as:
Count of participants · Participants
Number of Participants With Clinical Resolution Response Outcome
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Day 2 - Clinically Resolved01
Day 2 - Clinically Unresolved (CU)/Clinical Worsening (CW)1127
Day 3 - Clinically Unresolved (CU)/Clinical Worsening (CW)21
Day 4 - Clinically Resolved35
Day 4 - Clinically Unresolved (CU)/Clinical Worsening (CW)823
Day 5 - Clinically Resolved21
Day 6 - Clinically Resolved915
Day 6 - Clinically Unresolved (CU)/Clinical Worsening (CW)213
Other pre-specifiedNumber of Participants With Clinical Resolution Response at the ToC Visit

The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at ToC visit was defined as "Clinical Resolution Success (CRS)" when, in the opinion of the investigator, there was resolution of signs and symptoms of the uUTI present at Baseline (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterial therapy. "Clinical Resolution Failure (CRF)" was defined when investigator's assessment was Clinically Unresolved/Clinical Worsening or Indeterminate at ToC. Indeterminate was defined as refusal to consent to a clinical examination or failure to attend the ToC visit.

Time frame:
Day 10 to Day 13 (ToC Visit)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Resolution Response at the ToC Visit
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Clinical Resolution Success (CRS)1121
Clinically Unresolved (CU)/Clinical Worsening (CW)06
Indeterminate (Ind)01
Other pre-specifiedNumber of Participants With Clinical Resolution Response at the Follow-up (FU) Visit

The investigators were asked to record their impression of the clinical status of the participant with regard to the presenting uUTI (resolved/unresolved). Clinical resolution response at FU was defined as "CRS" when investigator's assessment was Clinically Resolved at both ToC and FU (SCR), i.e., resolution of signs and symptoms of the uUTI present at BL (and no worsening and no new signs and symptoms) and no requirement for the use of other antibacterials. "CRF" was defined when investigator's assessment was: Clinically Unresolved at ToC but Clinically Resolved at FU (DCR); Clinically Resolved at ToC but Clinically Unresolved at FU (CRr); Clinically Unresolved at both ToC and FU (CU/CW); or when participants refused to consent to a clinical exam, failed to attend the FU, or achieved SCR/DCR but received other systemic antibacterials before FU (Ind).

Time frame:
Day 25 to Day 31 (Follow-up Visit)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Resolution Response at the Follow-up (FU) Visit
ParticipantsNitrofurantoin + PlaceboGSK3882347+ Placebo
Clinical Resolution Success (CRS)1019
Delayed Clinical Resolution (DCR)03
Clinical Recurrence (CRr)11
Clinically Unresolved (CU)/Clinical Worsening CW)03
Indeterminate (Ind)02

Adverse events

Collected over All-cause mortality and SAEs were collected from the signing of informed consent up to the Follow-up Visit (up to Day 31). Non-SAEs were collected from the first dose of study intervention up to the Follow-up Visit (up to Day 31).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nitrofurantoin + Placebo0/31 (0%)0/31 (0%)10/31 (32.3%)
GSK3882347+ Placebo0/91 (0%)0/91 (0%)22/91 (24.2%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventNitrofurantoin + PlaceboGSK3882347+ Placebo
NauseaGastrointestinal disorders2/317/91
HeadacheNervous system disorders2/317/91
AnaemiaBlood and lymphatic system disorders2/312/91
Urinary tract infectionInfections and infestations0/314/91
Abdominal painGastrointestinal disorders1/311/91
Abdominal distensionGastrointestinal disorders1/310/91
BacteriuriaInfections and infestations1/310/91
Alanine aminotransferase increasedInvestigations1/311/91
PollakiuriaRenal and urinary disorders1/311/91
Vaginal dischargeReproductive system and breast disorders1/310/91

Baseline characteristics

Randomized analysis set included all participants who passed screening, entered the study, and were randomly assigned to study intervention. Due to potential data quality issues, 14 participants were excluded from the analysis set.

Age, Continuous
Age, Continuous(YEARS)Nitrofurantoin + PlaceboGSK3882347+ PlaceboTotal
Mean44.0 ± 14.8945.6 ± 14.4545.2 ± 14.52
Sex: Female, Male
Sex: Female, Male(Participants)Nitrofurantoin + PlaceboGSK3882347+ PlaceboTotal
Female3294126
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nitrofurantoin + PlaceboGSK3882347+ PlaceboTotal
White2878106
Black or African American31114
Asian145
Native Hawaiian or Other Pacific Islander011
08

Study locations

15 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Lomita, California 90717, United States
  • GSK Investigational Site
    Modesto, California 95350-5365, United States
  • GSK Investigational Site
    Doral, Florida 33166, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33016-1507, United States
  • GSK Investigational Site
    Palmetto Bay, Florida 33157, United States
  • GSK Investigational Site
    Sweetwater, Florida 33172, United States
  • GSK Investigational Site
    Chicago, Illinois 60643, United States
  • GSK Investigational Site
    The Bronx, New York 10456, United States
  • GSK Investigational Site
    Smithfield, Pennsylvania 15478, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77061, United States
  • GSK Investigational Site
    Missouri City, Texas 77459, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2024, 30 months.

Results were first posted in Mar 2026, 1 year 3 months after primary completion.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Dec 1, 2021
StartActual
May 18, 2022
Primary completionActual
Dec 3, 2024
CompletionActual
Dec 3, 2024
Results first posted
Mar 13, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05138822
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
May 18, 2022
Primary completion
Dec 3, 2024
Completion
Dec 3, 2024
Results posted
Mar 13, 2026
Last update
Mar 13, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK3882347

Start the discussion